Table 2.
Clinical, laboratory and histological characteristics at diagnosis
| <60 group (N = 286) | ≥60 group (N = 73) | p-value | |
|---|---|---|---|
| Age at diagnosis (year) | 37,5 (5–59) | 66 (60–84) | |
| Follow up (months) | 108 (1–516) | 72 (2–242) | <0.001 |
| Gender (male/female) | 64/222 | 15/58 | 0.874 |
| AIH Score (1) | 16 (10–22) | 17 (11–22) | 0.249 |
| Alkaline phosphatase (IU/l) | 154 (27–2197) | 140,5 (56–391) | 0.154 |
| Alanine aminotransferase (IU/l) | 442 (13–3478) | 302 (26–2272) | 0.004 |
| IgG (g/l) | 22,9 (8,16–75) | 23,4 (8,19–60,7) | 0.278 |
| ANA positive | 166/246 (68%) | 51/71 (72%) | 0.563 |
| SMA positive | 150/240 (63%) | 44/68 (65%) | 0.778 |
| AMA positive | 13/249 (5%) | 3/72 (4%) | 1.000 |
| SLA positive | 13/250 (5%) | 4/71 (6%) | 1.000 |
| p-ANCA positive | 42/250 (17%) | 13/71 (18%) | 0.725 |
| Cirrhosis at diagnosis | 81 (28%) | 25 (34%) | 0.310 |
| Concurrent autoimmune disease | 57 (20%) | 24 (33%) | 0.027 |
| HLA typing | (N = 144) | (N = 28) | |
| HLA DR3 | 88 (61%) | 15 (54%) | 0.529 |
| HLA DR4 | 35 (24%) | 9 (32%) | 0.477 |
| Histological features | (N = 249) | (N = 65) | |
| Interface hepatitis | 228 (92%) | 59 (91%) | 0.806 |
| Plasma cell infiltrate | 248 (99%) | 64 (99%) | 0.372 |
| Biliary changes | 16 (6%) | 9 (14%) | 0.068 |
| Mode of presentation | (N = 246) | (N = 70) | 0.034 |
| Asymptomatic | 38 (15%) | 14 (20%) | 0.365 |
| Insidious | 151 (61%) | 49 (70%) | 0.187 |
| Acute | 57 (23%) | 7 (10%) | 0.016 |
Median (range), Number (percentage), Number/Number known or measured (percentage)
Bold is significant